KL
AEON icon

KIM LLC’s AEON Biopharma AEON Stock Holding History

KIM LLC’s Portfolio AEON Stock Details AEON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-216
Closed -$16.3K – 42
2024
Q2 		$16.3K Buy
+216
New +$51.5K ﹤0.01% 137
2023
Q1 		– Sell
-3,472
Closed -$2.51M – 527
2022
Q4 		$2.51M Hold
3,472
– – 0.14% 185
2022
Q3 		$2.46M Hold
3,472
– – 0.11% 229
2022
Q2 		$2.45M Buy
+3,472
New +$2.45M 0.12% 234

Other funds holding AEON

PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FAM
Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
CG
Caprock Group Boise, Idaho $5.22B AUM 42.47% 1-Year Est. Return

KIM LLC's AEON Position: Q3 2024 in Review

KIM LLC sold out of AEON Biopharma (AEON) in Q3 2024, closing a stake of 216 shares — an estimated $16.3K sold.

KIM LLC first reported a position in AEON in Q2 2022 and held it in 4 quarters. The position peaked at $2.51M in Q4 2022. 30 funds tracked by Wall St. Rank hold AEON as of Q3 2024.

  • KIM LLC reported no remaining AEON Biopharma position as of Q3 2024 after selling out during the quarter.
  • KIM LLC sold 216 AEON Biopharma shares in Q3 2024, an estimated $16.3K.
  • KIM LLC first reported a position in AEON Biopharma in Q2 2022 and held it in 4 quarters.
  • KIM LLC's AEON Biopharma position peaked at $2.51M in Q4 2022.
  • 30 funds tracked by Wall St. Rank held AEON Biopharma as of Q3 2024.

Based on KIM LLC's 13F filing for Q3 2024, filed 13 Nov 2024.